ClinicalTrials.gg
Active, not recruitingNCT06681324CALLISTOUpdated Oct 28, 2026

Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

A Phase 2 interventional study of AZD7798 and Placebo in Crohn's Disease, sponsored by AstraZeneca. Active, not recruiting at 17 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AstraZeneca · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Crohn Disease by AstraZeneca — none open to participants now, 2 under way, none of them phase 3. Crohn Disease · AstraZeneca.

Enrollment
10th of 13
24 · median 48
Started
2024
with 2 others
Phase 2
5 of 13
none open now
Registered
13th of 13
by date

Among the 13 studies in Crohn Disease by AstraZeneca, this one is the 10th largest by enrollment, is one of 3 that started in 2024, is one of 5 in phase 2, and was the 13th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 13 studies in Crohn Disease by AstraZeneca is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Crohn Disease by AstraZeneca as a file.
02

Study summary

The purpose of this study is to evaluate safety, tolerability, and effect on mucosal repair of AZD7798 compared with placebo in participants with active ileal Crohn's disease and an ileostomy.

Read the detailed description

This is a participant-and investigator-blind, randomized, parallel-group, placebo controlled phase II study designed to evaluate safety, tolerability, and mucosal repair with AZD7798 in participants with active ileal Crohn's disease and an ileostomy. This study will include a screening period, an induction period, an open-label maintenance period, and a follow-up period. Approximately 30 participants will be randomized globally to receive either AZD7798 or placebo during 12-week participant- and investigator- blind induction period. At week 12 after induction period, all eligible participants will enter 40-week open label maintenance period. Follow-up visits will take place 8 weeks and 18 weeks after the last dose of study intervention, whether this occurs during the induction period or the open-label maintenance period.

03

Conditions studied

  • Crohn's Disease

Keywords

  • Crohn's disease
  • ileostomy
  • inflammation
  • small bowel
  • stoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 80 years of age.
  • Diagnosis of Crohn's disease established with clinical AND at least one of imaging, endoscopic, and/or histopathologic evidence.
  • Ileostomy (including Kock pouch) for at least 3 months.
  • Prior to screening endoscopy, clinical suspicion of active ileal inflammation based on at least one of the following: previous endoscopy, imaging (CT, MRI, IUS), or FCP above upper reference limit.
  • Active ileal Crohn's disease as determined by active intestinal mucosal inflammation, as demonstrated on video recorded ileoscopy performed during the screening period and scored by a blinded central reader with agreement on the SES CD ≥ 4 of the ileal segment from 5 to 25 cm (20cm length) proximal to the stoma. Participants with inflammation in additional intestinal segments are not excluded.
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Concomitant additional gastrointestinal luminal inflammatory diseases including, but not limited to, infectious enteritis, ischaemic bowel, inflammation and strictures caused by previous radiation therapy
  • Strictures/stenoses preventing passage of endoscope throughout the specified segment (up to 25 cm of ileum)
  • Short bowel syndrome
  • Within 3 months prior to screening:

    1. Diagnosis of peritonitis or need treatment of peritonitis
    2. Bowel perforation or evidence of obstruction
  • All intrabdominal, cutaneous and perianal/perirectal abscesses and fistulae are excluded with exception of: cutaneous and perianal/perirectal abscesses and/or fistulae which are adequately drained 4 weeks prior to randomization, and intra-abdominal fistulae between bowel segments only without complications
  • Ongoing or expected nutritional dependency on total enteral or parenteral nutrition during study (partial nutrition acceptable).
  • In participants with any remaining colon and/or rectum, evidence of an increased risk of colorectal cancer, including:

    1. Adenomatous colonic/rectal polyps that have not been removed
    2. Intestinal dysplasia
    3. Not undertaking appropriate surveillance, if indicated, for colorectal dysplasia/
    4. Family history of early onset colorectal cancer, established diagnosis of HNPCC pancolitis for >8years duration without up-to-date colorectal cancer surveillance (can be performed during screening endoscopy if considered clinically appropriate by Investigator)
  • Reversal of ileostomy or formation of J-pouch planned prior to end of study period.
  • High-output stoma (eg, > 2000 mL/24 hours) associated with volume depletion and/or electrolyte disturbance to the extent that, in the opinion of the Investigator, it may put the participant at undue risk because of participation in the study, or impact their ability to participate in the study or interfere with the interpretation of study data.
  • Any of the following treatments within the specified time period:

    1. An anti-TNF biologic within 8 weeks prior to randomization, unless therapeutic drug monitoring is performed, and drug concentrations are undetectable.
    2. Any biologic targeting immune response other than an anti-TNF (including vedolizumab and ustekinumab) within 12 weeks prior to randomization unless validated therapeutic drug monitoring is performed, and drug concentrations are indetectable. Biologics not targeting immune response (eg, denosumab) will not be .
    3. Other advanced small molecule treatments for Crohn's disease (including JAK inhibitors or S1P modulators) within 4 weeks prior to randomization
    4. Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, or tacrolimus within 4 weeks prior to randomization
    5. Treatment with apheresis (eg, Adacolumn, Cellsorba) within 4 weeks prior to randomization
    6. Administration of any within 4 weeks prior to randomization, or planned administration of any such vaccine during the study
    7. Faecal microbiota transplantation within 4 weeks prior to randomization
    8. Regular intake of NSAIDs within 12 weeks prior to screening ileoscopy and during the study (defined as at least times per week for more than 3 months; not applicable to daily aspirin use up to 325 mg per day)
    9. Lymphocyte-depleting treatment, including, but not limited to rituximab, within 12 months prior to randomization
  • Any changes in dosing of the following medications prior to screening ileoscopy as outlined

    1. 5-aminosalicylates within 2 weeks
    2. Oral within 2 weeks. Also excluded if on stable dosing of steroids exceeding the following dose equivalents:

    (i) Systemic steroids > 20 mg/day prednisolone dose or equivalent (ii) Locally targeted steroids exceeding maximum budesonide dose or equivalent [9 mg/day] (c) Immunomodulators (thiopurines or methotrexate) within 4 weeks (d) Antibiotic therapy for the treatment of Crohn's disease, eg, ciprofloxacin or metronidazole within 2 weeks (e) Probiotics within 2 weeks

  • Evidence of recent or currently active infection, including use of IV or oral antibiotics for documented infection within 30 days prior to screening. Topical antimicrobials or antimicrobials for the treatment of uncomplicated urinary tract infection may be allowed at the Medical Monitor's discretion.
  • Evidence of chronic or C infection defined as:

    1. HBV: HBsAg positive or HBcAb positive
    2. : Positive result for HCV Ab is exclusionary unless HCV RNA is undetectable, and at least 12 weeks post anti-viral treatment of HCV (if treated).
  • History of TB (active or latent) unless an appropriate course of treatment has been completed.
  • Positive diagnostic TB test at screening (defined as positive QuantiFERON test). In cases where the QuantiFERON test is indeterminate, the patient may have the test repeated once and if their second test is negative, they will be eligible. In the event a second test is also indeterminate, the Investigator has the option to undertake PPD testing. If the PPD reaction is \<5mm, then the patient is eligible. If the reaction is ≥ 5 mm, or PPD testing is not undertaken, the patient is not eligible. If there has been a history of completed treatment for TB and, per specialist opinion, a positive QuantiFERON test reflects previous infection only and no current active or latent infection, the participant could be included.
  • History of serious opportunistic infection (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) within 12 months prior to screening
  • Symptomatic herpes zoster infection within 3 months prior to screening.
  • Positive C. difficile toxin test at screening.
  • Any identified immunodeficiency, congenital and/or acquired aetiologies, including, but not limited to:

    1. infection (patients with positive results of HIV testing by the central laboratory will be excluded)
    2. Splenectomy
    3. Previous allogenic bone marrow transplant or history of organ or cell-based transplantation (eg, islet cell transplantation or stem cell transplantation) with the exception of corneal transplant
    4. Primary immune deficiency diseases, excluding selective IgA deficiency.
  • Abnormal laboratory results at screening:

    1. \< 8 g/dL
    2. \< 1,500/μL (or \< 1.5 × 109/L); a re-test is allowed during screening in cases of mild neutropenia clinically suspected to be transient
    3. Lymphocytes \< 500/μL (or \< 0.5 × 109/L)
    4. Liver function tests: /ALT/ALP > 2 × ; or TBL ≥ 1.5 × ULN (isolated > 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%)
    5. according to CKD-EPI formula \< 30 mL/min
    6. Any other abnormal laboratory results at screening, which, in the opinion of the Investigator, will prevent the participant from completing the study or will interfere with the interpretation of the study results
  • Prolonged interval > 450 ms (or > 480 ms for patients with bundle branch block) or congenital long-QT syndrome or family history of long-QT syndrome or sudden cardiac death in age \< 40 years. In case of borderline result or concern for artifact, triplicate ECGs should be collected within a 10-minute period, and the averaged value calculated for decision making.
  • cardiovascular conditions including:

    1. Acute coronary syndrome (acute myocardial infarction, unstable angina), coronary intervention with percutaneous coronary intervention/coronary artery bypass surgery, stroke, within 6 months prior to screening
    2. Decompensated heart failure requiring hospitalisation, or Class III/IV heart failure, within 6 months prior to screening
    3. Untreated second degree, Mobitz II or third degree atrioventricular-block, significant sinus node dysfunction/pause or therapy-requiring tachyarrhythmia. Patients with atrial fibrillation/flutter and optimally controlled ventricular rate (resting rate \< 100 bpm) may be eligible as judged by the Investigator
    4. Hypertrophic cardiomyopathy or clinically significant valvular heart disease which, in the opinion of the Investigator, will prevent the patient from completing the study or will interfere with the interpretation of the study results.
  • Reproduction:

    1. Pregnant and breastfeeding participants, or those planning to breastfeed during the study
    2. FOCBP, unless they agree to complete abstinence or to use a highly effective method AND barrier method from enrollment until 18 weeks following last drug administration. FONCBP may be included.
  • Current malignancy or history of malignancy, except for:

    1. Basal cell carcinoma, localised squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided the patient is in remission and curative therapy was completed at least 12 months prior to screening;
    2. Other non-gastrointestinal malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to screening.
  • Current significant major or unstable respiratory disease, heart disease, cerebrovascular disease, haematological disease, hepatic disease including large duct primary sclerosing cholangitis with jaundice, recurrent cholangitis or cirrhosis, renal disease, gastrointestinal disease, or other major disease other than active Crohn's disease. Gilbert's syndrome is not exclusionary. Small duct primary sclerosing cholangitis is not exclusionary if liver biomarkers are normal and there is no concern for cirrhosis.
  • Current enrolment in another interventional study or treatment with any drug within 4 months (or 5 half-lives, whichever is longer) prior to screening
  • Unstable lifestyle factors, such as alcohol use to excess or recreational drug use, to the extent that in the opinion of the Investigator they would interfere with the ability of a patient to complete the study.
  • Patients committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  • Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  • Previous randomization in the present study.
  • Investigator concerns regarding patient's willingness and ability to attend all study visits, comply with the study procedures, read in order to complete questionnaires, or to complete the study period.
  • to the IMP or any of its .
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    AZD7798

    AZD7798

    Drug: AZD7798

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • AZD7798

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Summary of any adverse events and also by MedDRA SOC and Preferred term

    Time frame: from Week 0 to Week 12

  2. Number of participants with abnormal Vital signs: Blood pressure

    Systolic and diastolic blood pressure will be summarized by descriptive statistics

    Time frame: from Week 0 to Week 12

  3. Number of participants with abnormal Vital signs: Pulse rate

    Pulse rate will be summarized by descriptive statistics

    Time frame: from Week 0 to Week 12

  4. Number of participants with abnormal values in haematology: complete blood count (CBC)

    The variables platelet count, red blood cell (RBC) count, haemoglobin, haematocrit will be summarized with descriptive statistics

    Time frame: from Week 0 to Week 12

  5. Number of participants with abnormal values in haematology: white blood cell (WBC) count

    The variables neutrophils, lymphocytes, monocytes, eosinophils, and basophils will be summarized with descriptive statistics

    Time frame: from Week 0 to Week 12

  6. Number of participants with abnormal values in haematology: RBC

    The variables mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and percentage of reticulocytes will be summarized with descriptive statistics

    Time frame: from Week 0 to Week 12

  7. Number of participants with abnormal values in clinical chemistry: kidney function

    The variables creatinine and blood urea nitrogen (BUN) will be summarized with descriptive statistics

    Time frame: from Week 0 to Week 12

  8. Number of participants with abnormal values in clinical chemistry: electrolytes

    The variables potassium, sodium, and calcium will be summarized with descriptive statistics

    Time frame: from Week 0 to Week 12

  9. Number of participants with abnormal values in clinical chemistry: liver function

    The variables ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), and ALP (alkaline phosphatase), and albumin will be summarized with descriptive statistics

    Time frame: from Week 0 to Week 12

  10. Number of participants with abnormal values in clinical chemistry: hs-CRP

    The variable hs-C-reactive protein will be summarized with descriptive statistics

    Time frame: from Week 0 to Week 12

  11. Number of participants with abnormal values in clinical chemistry: glucose

    The variable glucose will be summarized with descriptive statistics

    Time frame: from Week 0 to Week 12

  12. Number of participants with abnormal values in ECG readings

    12-lead ECGs will be obtained using an ECG machine, that automatically measures RR/HR, PR, QRS, QT and Corrected QT (QTc) intervals, and summarized with descriptive statistics

    Time frame: from Week 0 to Week 12

Secondary outcomes

  1. Difference in mean change from baseline in endoscopic score between active and placebo

    Simple Endoscopic Score for Crohn's Disease (SES-CD) is based on the evaluation of ileum, and the presence and size of ulcerations and the extent of the inflammatory area and stenosis are assessed. The segment is scored from 0 to 12, higher scores indicating more active disease

    Time frame: Week 12

  2. Number of participants with endoscopic response

    Endoscopic response is defined as ≥ 50% decrease from baseline in SES-CD total score and based on the evaluation of ileum and the presence and size of ulcerations and the extent of the inflammatory area and stenosis are assessed. The segment is scored from 0 to 12, higher scores indicating more active disease

    Time frame: Week 12

  3. Number of participants with endoscopic remission

    Endoscopic remission is defined as SES-CD total score \< 4 and at least 2 point reduction from baseline with no sub score \> 1 in any individual variable. SES-CD is based on the evaluation of ileum, and the presence and size of ulcerations and the extent of the inflammatory area and stenosis are assessed. The segment is scored from 0 to 12, higher scores indicating more active disease

    Time frame: Week 12

  4. Serum AZD7798 concentration

    Serum AZD7798 concentration (PK)

    Time frame: up to 52 Weeks

  5. Incidence of anti-drug antibody response

    Incidence of anti-drug antibody (ADA) response - number and percentages with a positive ADA result

    Time frame: up to 52 Weeks

  6. Titre of anti-drug antibody response

    Titre of anti-drug antibody (ADA) response - immunogenicity titre will be summarized descriptively as a continuous variable, only for ADA positive tests

    Time frame: up to 52 Weeks

  7. Number of participants with adverse events in active treatment

    Summary of any adverse events and also by MedDRA SOC and Preferred term

    Time frame: from Week 12 to Week 52

  8. Number of participants with abnormal vital signs: Blood pressure

    Systolic and diastolic blood pressure will be summarized by descriptive statistics

    Time frame: from Week 12 to Week 52

  9. Number of participants with abnormal vital signs: Pulse rate

    Pulse rate will be summarized by descriptive statistics

    Time frame: from Week 12 to Week 52

  10. Number of participants with abnormal values in haematology: complete blood count (CBC)

    The variables platelet count, red blood cell (RBC) count, haemoglobin, haematocrit will be summarized with descriptive statistics

    Time frame: from Week 12 to Week 52

  11. Number of participants with abnormal values in haematology: white blood cell (WBC) count

    The variables neutrophils, lymphocytes, monocytes, eosinophils, and basophils will be summarized with descriptive statistics

    Time frame: from Week 12 to Week 52

  12. Number of participants with abnormal values in haematology: RBC

    The variables mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and percentage of reticulocytes will be summarized with descriptive statistics

    Time frame: from Week 12 to Week 52

  13. Number of participants with abnormal values in clinical chemistry: kidney function

    The variables creatinine and blood urea nitrogen (BUN) will be summarized with descriptive statistics

    Time frame: from week 12 to week 52

  14. Number of participants with abnormal values in clinical chemistry: electrolytes

    The variables potassium, sodium, and calcium will be summarized with descriptive statistics

    Time frame: from Week 12 to Week 52

  15. Number of participants with abnormal values in clinical chemistry: liver function

    The variables ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), and ALP (alkaline phosphatase), and albumin will be summarized with descriptive statistics

    Time frame: from Week 12 to Week 52

  16. Number of participants with abnormal values in clinical chemistry: hs-CRP

    The variable hs-C-reactive protein will be summarized with descriptive statistics

    Time frame: from Week 12 to Week 52

  17. Number of participants with abnormal values in clinical chemistry: glucose

    The variable glucose will be summarized with descriptive statistics

    Time frame: from Week 12 to Week 52

  18. Number of participants with abnormal values in ECG readings

    12-lead ECGs will be obtained using an ECG machine, that automatically measures RR/HR, PR, QRS, QT and Corrected QT (QTc) intervals, and summarized with descriptive statistics

    Time frame: from week 12 to week 52

07

Study locations

17 sites
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Padova, 35121, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Nijmegen, 6525 GA, Netherlands
  • Research Site
    Warsaw, 04-501, Poland
  • Research Site
    Linköping, 581 85, Sweden
  • Research Site
    Stockholm, 17176, Sweden
  • Research Site
    Kyiv, 02002, Ukraine
  • Research Site
    Kyiv, 04210, Ukraine
  • Research Site
    Vinnytsia, 21029, Ukraine
  • Research Site
    Birmingham, B15 2GW, United Kingdom
  • Research Site
    Cambridge, CB2 0XY, United Kingdom
  • Research Site
    London, E1 1FR, United Kingdom
  • Research Site
    London, NW10 7NS, United Kingdom
  • Research Site
    London, WC1E 6AG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Aug 2026, 19 months.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 19 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2024
First posted
Nov 8, 2024
StartActual
Dec 11, 2024
Primary completionActual
Aug 10, 2026
CompletionEst.
Sep 3, 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06681324
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Dec 11, 2024
Primary completion
Aug 10, 2026
Completion
Sep 3, 2027 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD7798

Start the discussion